Healthcare

The move came on a day when the broader index finished modestly higher but with sharp divergence beneath the surface. At the time of writing, the healthcare sector rose around 2.56% and the information technology sector surged around 4.97%, making them the two clear …

Telix Pharmaceuticals occupies a relatively rare position in the Australian biotech landscape: it has transitioned from a clinical-stage company to a commercially generating business with substantial revenue. That shift, driven by the US commercial success of Illuccix, places ASX: TLX in a different category …

Neurizon Therapeutics Limited (ASX: NUZ) announced that new preclinical mechanism-of-action data for its lead amyotrophic lateral sclerosis (ALS) candidate, NUZ-001, would be presented at the BIO International Convention 2026, a leading biotechnology and life science partnering forum.

Algorae Pharmaceuticals Ltd (ASX:1AI) attracted renewed attention on 23 June after its shares rose 10% to AUD 0.011, representing a gain of AUD 0.001 during the session. The stock opened at AUD 0.011, traded between AUD 0.010 and AUD 0.011 and closed at the …

Noxopharm Ltd (ASX:NOX) returned to investors' radar on 23 June after its shares advanced 8.22% to AUD 0.079, adding AUD 0.006 during the session. The stock opened at AUD 0.076 and maintained steady momentum throughout the day, reaching an intraday high of AUD 0.079 …

Medibank Private (ASX:MPL) has long held a place on the watchlists of investors seeking defensive exposure to Australia's healthcare sector. As the country's largest private health insurer by policyholder numbers, Medibank commands a significant share of the roughly $30 billion Australian private health insurance …

Elevra Lithium (ASX:ELV) has emerged as one of the most closely watched lithium names on the ASX heading into the second half of 2026. Formed through the August 2025 merger of Sayona Mining and Piedmont Lithium and dual-listed on the Nasdaq as ELVR, Elevra …